No mutations in the CYLD gene were identified in T-ALL patients, indicating that in contrast to the multiple myeloma setting, where CYLD mutations were detected [29,30], this gene is inhibited at the transcriptional level. The gene discussed is CYLD; the disease is plasma cell myeloma.